Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

MLA

Haronikova, Lucia, et al. “Resistance Mechanisms to Inhibitors of P53-MDM2 Interactions in Cancer Therapy: Can We Overcome Them?” Cellular & Molecular Biology Letters, vol. 26, no. 1, Dec. 2021, pp. 1–33. EBSCOhost, https://doi.org/10.1186/s11658-021-00293-6.

APA

Haronikova, L., Bonczek, O., Zatloukalova, P., Kokas-Zavadil, F., Kucerikova, M., Coates, P. J., Fahraeus, R., & Vojtesek, B. (2021). Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them? Cellular & Molecular Biology Letters, 26(1), 1–33. https://doi.org/10.1186/s11658-021-00293-6

Chicago

Haronikova, Lucia, Ondrej Bonczek, Pavlina Zatloukalova, Filip Kokas-Zavadil, Martina Kucerikova, Philip J. Coates, Robin Fahraeus, and Borivoj Vojtesek. 2021. “Resistance Mechanisms to Inhibitors of P53-MDM2 Interactions in Cancer Therapy: Can We Overcome Them?” Cellular & Molecular Biology Letters 26 (1): 1–33. doi:10.1186/s11658-021-00293-6.